Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 clinical data for LPCN 1154 have been selected for oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held May 26–29, 2026, in Miami, FL. Oral Presentation details Title: Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154 Presenter: Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine Session: Pharmaceutical Pipeline (Oral Presentation) Date: Tuesday, May 26, 2026 Time: 3:20 PM ET Location: Loews Miami Beach Hotel, Miami, FL The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).